Literature DB >> 18288127

Short- and long-term risk of cardiovascular events in white-coat hypertension.

S D Pierdomenico1, D Lapenna, R Di Mascio, F Cuccurullo.   

Abstract

The prognostic impact of white-coat hypertension is not yet completely clear. In this study, we investigated cardiovascular outcome in sustained hypertension, white-coat hypertension and normotension in the short and long term. The occurrence of fatal and nonfatal cardiovascular events was evaluated in 1732 subjects with clinical hypertension (1333 with sustained and 399 with white-coat hypertension) and 305 with normotension. White-coat hypertension was defined as clinical hypertension and daytime blood pressure <135/85 mm Hg. During the period of observation (mean 6.4 years, range 0.7-13.1), 152 cardiovascular events occurred. The event rate per 100 patient-years in subjects with normotension, white-coat and sustained hypertension was 0.38, 0.44 and 1.58, respectively. Event-free survival was significantly different among the groups (P<0.0001). After adjustment for several covariates, Cox regression analysis showed that cardiovascular risk was significantly higher in patients with sustained than in those with white-coat hypertension (relative risk (RR) 3.32, 95% confidence interval (CI) 1.81-6.12, P=0.0001), whereas there was no significant difference between normotension and white-coat hypertension. When events were analysed separately, cardiac and cerebrovascular risk were significantly higher in sustained than in white-coat hypertension (RR 4.16, 95% CI 1.48-11.6, P=0.007, and RR 4.12, 95% CI 1.62-10.5, P=0.003, respectively) and not significantly different between white-coat hypertension and normotension. Event-free survival had the same trend for the whole period of observation both when cardiovascular events were examined together and when cardiac and cerebrovascular events were analysed separately. In this study, cardiovascular risk in white-coat hypertension was significantly lower than that in sustained hypertension and not significantly different from normotension both in the short and long term.

Entities:  

Mesh:

Year:  2008        PMID: 18288127     DOI: 10.1038/jhh.2008.6

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  12 in total

Review 1.  Prevalence of white-coat and masked hypertension in national and international registries.

Authors:  Manuel Gorostidi; Ernest Vinyoles; José R Banegas; Alejandro de la Sierra
Journal:  Hypertens Res       Date:  2014-10-16       Impact factor: 3.872

2.  White coat hypertension and obstructive sleep apnea.

Authors:  Li Li; Li-Zhu Guo; Jie Li; Ying Wang; Xin Liu; Ya-Hui Lv; Chang-Sheng Ma
Journal:  Sleep Breath       Date:  2015-02-14       Impact factor: 2.816

Review 3.  Closer look at white-coat hypertension.

Authors:  Nurver Turfaner Sipahioglu; Fikret Sipahioglu
Journal:  World J Methodol       Date:  2014-09-26

Review 4.  Diagnosis and management of patients with white-coat and masked hypertension.

Authors:  Giuseppe Mancia; Michele Bombelli; Gino Seravalle; Guido Grassi
Journal:  Nat Rev Cardiol       Date:  2011-08-09       Impact factor: 32.419

5.  White coat hypertension is more risky than prehypertension: important role of arterial wave reflections.

Authors:  Shih-Hsien Sung; Hao-Min Cheng; Kang-Ling Wang; Wen-Chung Yu; Shao-Yuan Chuang; Chih-Tai Ting; Edward G Lakatta; Frank C P Yin; Pesus Chou; Chen-Huan Chen
Journal:  Hypertension       Date:  2013-04-22       Impact factor: 10.190

Review 6.  An Update on Masked Hypertension.

Authors:  D Edmund Anstey; Daniel Pugliese; Marwah Abdalla; Natalie A Bello; Raymond Givens; Daichi Shimbo
Journal:  Curr Hypertens Rep       Date:  2017-10-25       Impact factor: 5.369

7.  Is Daytime Systolic Load an Important Risk Factor for Target Organ Damage in Pediatric Hypertension?

Authors:  Seçil Conkar; Ebru Yılmaz; Şükriye Hacıkara; Sibel Bozabalı; Sevgi Mir
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-07-03       Impact factor: 3.738

8.  White-Coat Isolated Systolic Hypertension Is a Risk Factor for Carotid Atherosclerosis.

Authors:  Efstathios Manios; Fotios Michas; Kimon Stamatelopoulos; Eleni Koroboki; Aikaterini Lykka; Charitini Vettou; Konstantinos Vemmos; Nikolaos Zakopoulos
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-08-02       Impact factor: 3.738

Review 9.  White-coat hypertension should not be treated in subjects with diabetes.

Authors:  Michael Bursztyn; Iddo Z Ben-Dov
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

10.  Discrepancy between tonometric ambulatory and cuff-based office blood pressure measurements in patients with type 1 diabetes.

Authors:  Simone Theilade; Maria Lajer; Christel Joergensen; Frederik Persson; Peter Rossing
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-08-03       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.